LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Home・Aandelen Lijst・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Gesloten

4.06 2.53

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.88

Max

4.07

Belangrijke statistieken
By Trading Economics
Inkomsten	5.5M -28M
Verkoop	8.2M 13M
EPS	-0.47
Winstmarge	-208.694
Werknemers	172
EBITDA	8.7M -27M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+250.88% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-21M 234M
Vorige openingsprijs	1.53
Vorige sluitingsprijs	4.06

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

3.17 / 3.4644 Steun & Weerstand

Voyager Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 dec 2025, 21:41 UTC

Acquisities, Fusies, Overnames

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

24 dec 2025, 14:57 UTC

Acquisities, Fusies, Overnames

Accenture to Acquire Cabel Industry from Fibonacci Group

24 dec 2025, 12:48 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead

24 dec 2025, 12:21 UTC

Belangrijke Marktbewegers

Nike Shares Tick Up After Apple CEO Tim Cook Buys $2.9 Million of Its Stock

24 dec 2025, 22:22 UTC

Acquisities, Fusies, Overnames

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 dec 2025, 19:35 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 dec 2025, 19:35 UTC

Marktinformatie

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 dec 2025, 19:09 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

24 dec 2025, 19:09 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 dec 2025, 19:06 UTC

Marktinformatie

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

24 dec 2025, 19:03 UTC

Marktinformatie

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

24 dec 2025, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

24 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

24 dec 2025, 17:08 UTC

Acquisities, Fusies, Overnames

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dec 2025, 16:53 UTC

Acquisities, Fusies, Overnames

Nike Climb Boosts Dow, S&P 500 -- WSJ

24 dec 2025, 16:31 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

24 dec 2025, 16:28 UTC

Acquisities, Fusies, Overnames

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

24 dec 2025, 16:17 UTC

Marktinformatie

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

24 dec 2025, 15:33 UTC

Acquisities, Fusies, Overnames

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

24 dec 2025, 15:30 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec 2025, 15:19 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec 2025, 14:49 UTC

Acquisities, Fusies, Overnames

Mexico's Ollamani Sells Stake in Azteca Stadium

24 dec 2025, 14:19 UTC

Marktinformatie

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

24 dec 2025, 14:08 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec 2025, 14:06 UTC

Marktinformatie

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

24 dec 2025, 13:24 UTC

Marktinformatie

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

24 dec 2025, 12:59 UTC

Acquisities, Fusies, Overnames

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dec 2025, 12:51 UTC

Acquisities, Fusies, Overnames

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

24 dec 2025, 12:38 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

Peer Vergelijking

Prijswijziging

Voyager Therapeutics Inc Prognose

Koersdoel

By TipRanks

250.88% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 14 USD 250.88%

Hoogste 25 USD

Laagste 8 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Voyager Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Voyager Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.17 / 3.4644Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.